Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-12-04

FDA Approved: VIMIZIM — Supplemental Application (BioMarin Pharmaceutical Inc.)

View source ↗

Summary

FDA approved a supplemental application for VIMIZIM (elosulfase alfa) from BioMarin Pharmaceutical.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • VIMIZIM (Elosulfase alfa)

Snippet

SUPPL AP for VIMIZIM (ELOSULFASE ALFA)